[
  {
    "ts": null,
    "headline": "There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings",
    "summary": "Soft earnings didn't appear to concern Bio-Techne Corporation's ( NASDAQ:TECH ) shareholders over the last week. We did...",
    "url": "https://finnhub.io/api/news?id=0fbd23ae46fd864b4689831b256c43007e116bb4855073f841df387cae8a070f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770834754,
      "headline": "There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings",
      "id": 139048288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Soft earnings didn't appear to concern Bio-Techne Corporation's ( NASDAQ:TECH ) shareholders over the last week. We did...",
      "url": "https://finnhub.io/api/news?id=0fbd23ae46fd864b4689831b256c43007e116bb4855073f841df387cae8a070f"
    }
  },
  {
    "ts": null,
    "headline": "What Are Wall Street Analysts' Target Price for Bio-Techne Stock?",
    "summary": "Although Bio-Techne has underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=8350a1a49a16932fa2c4038cd8746a7164e1ffc1015c97b704a6d6c66c1e787c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770829460,
      "headline": "What Are Wall Street Analysts' Target Price for Bio-Techne Stock?",
      "id": 139049693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Although Bio-Techne has underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=8350a1a49a16932fa2c4038cd8746a7164e1ffc1015c97b704a6d6c66c1e787c"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne Announces Changes to its Leadership Team",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.",
    "url": "https://finnhub.io/api/news?id=d56f46ae335de8f216e8a704810c3da1dc3216e0a25aae278fd9940319343805",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770818400,
      "headline": "Bio-Techne Announces Changes to its Leadership Team",
      "id": 139042766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.",
      "url": "https://finnhub.io/api/news?id=d56f46ae335de8f216e8a704810c3da1dc3216e0a25aae278fd9940319343805"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne Corp (NASDAQ:TECH) Passes Key Quality Investing Screen",
    "summary": "Bio-Techne Corp (TECH) emerges as a top quality stock, showing strong earnings growth, high capital returns, and a robust financial position for long-term investors.",
    "url": "https://finnhub.io/api/news?id=504e7f2ea7c2623e7e60e57974d85668dbdab5752cb64017688363471ec077f6",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770805281,
      "headline": "Bio-Techne Corp (NASDAQ:TECH) Passes Key Quality Investing Screen",
      "id": 139040646,
      "image": "https://www.chartmill.com/images/uploads/thumbnail_article_luc_kroeze_c1f44c837d.webp",
      "related": "TECH",
      "source": "ChartMill",
      "summary": "Bio-Techne Corp (TECH) emerges as a top quality stock, showing strong earnings growth, high capital returns, and a robust financial position for long-term investors.",
      "url": "https://finnhub.io/api/news?id=504e7f2ea7c2623e7e60e57974d85668dbdab5752cb64017688363471ec077f6"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Bio-Techne’s Q4 Earnings Call",
    "summary": "Bio-Techne’s fourth quarter was defined by flat revenue performance, yet the company exceeded Wall Street’s expectations on both top and bottom lines, prompting a positive market response. Management attributed this to continued strength from large pharmaceutical customers and sequential improvement in most product categories, offset by temporary headwinds in cell therapy orders due to recent FDA Fast Track designations. CEO Kim Kelderman highlighted that core reagents, proteomic analysis instru",
    "url": "https://finnhub.io/api/news?id=c491866342562ba94f3e6c6f43bd554f58185ad2d8b0c4abf24a1c48f5ba51d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770788204,
      "headline": "5 Insightful Analyst Questions From Bio-Techne’s Q4 Earnings Call",
      "id": 139042767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne’s fourth quarter was defined by flat revenue performance, yet the company exceeded Wall Street’s expectations on both top and bottom lines, prompting a positive market response. Management attributed this to continued strength from large pharmaceutical customers and sequential improvement in most product categories, offset by temporary headwinds in cell therapy orders due to recent FDA Fast Track designations. CEO Kim Kelderman highlighted that core reagents, proteomic analysis instru",
      "url": "https://finnhub.io/api/news?id=c491866342562ba94f3e6c6f43bd554f58185ad2d8b0c4abf24a1c48f5ba51d5"
    }
  }
]